Yoshinao Takeuchi

  • Citations Per Year
Learn More
BACKGROUND Influenza control based on mass vaccination of schoolchildren was implemented in Japan in the 1960s and was associated with a decrease in the overall mortality rate. The program was discontinued in 1994. The discontinuation was followed by a seasonal increase in the mortality rate. Lately, young children and elderly persons have been receiving(More)
A total of 141 children with community-acquired pneumonia (CAP) were studied prospectively to determine the causative microorganisms. Microbial investigations included examination of postnasal swabs, cultures, polymerase chain reaction (PCR), and serology. The atypical pathogens occurring most frequently were Mycoplasma pneumoniae (58 patients [41.1%]),(More)
We evaluated the performance of an improved version of Espline Influenza A & B-N (Fujirebio Inc., Japan), an immunochromatography test using enzyme immunoassay for rapid diagnosis of influenza A and B. The test produced positive results for four strains of influenza viruses and thirty-one influenza viral antigens and negative results for all of thirty(More)
We evaluated a flow-through immunoassay for rapid detection of influenza A and B viral antigens, RapidTesta FLU AB (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan), by using 507 specimens collected from patients with influenza-like symptoms during the 2002/2003 influenza season in Japan. The specimens consisted of 239 nasal swabs and 268 nasal aspirates;(More)
We investigated the effectiveness of oseltamivir treatment against influenza virus infection in children. We treated 131 patients (mean age, 5.8 +/- 3.6 years) with oseltamivir (4 mg/kg/day for 5 days) during the 2001-2002 epidemic. All of the patients had been diagnosed with influenza using a rapid diagnosis kit. When treatment was initiated within 48(More)
During the influenza season, outbreaks of influenza may occur in the pediatric wards due to spread from the patients hospitalized with influenza, or from those hospitalized during the latency period and develop influenza afterwards. Post-exposure prophylaxis with neuraminidase inhibitors has been reported to be effective in preventing outbreaks among(More)
Amantadine is the first antiviral drug for human which was developed by duPont chemical company in 1964. Amantadine causes a selective, dose-related effectiveness of type A influenza virus and cost performance is very high. Amantadine should be given within 48 hours from onset of influenza. Daily doses should not exceed 150 mg in children, 200 mg in adults(More)
We investigated the antibody responses and clinical adverse reactions after immunization with live combined measles and rubella vaccine (HF vaccine) in 442 healthy children, aged 12-90 months of age. We obtained 368 paired sera. Among them, 363 were initially sero-negative against measles virus and 343 (94.5%) became sero-positive after immunization.(More)